Document and Entity Information
Document and Entity Information | 6 Months Ended |
Jun. 30, 2024 | |
Document And Entity Information [Abstract] | |
Document Type | 6-K |
Amendment Flag | false |
Document Period End Date | Jun. 30, 2024 |
Entity Registrant Name | EVOGENE LTD. |
Entity Central Index Key | 0001574565 |
Current Fiscal Year End Date | --12-31 |
Document Fiscal Period Focus | Q2 |
Document Fiscal Year Focus | 2024 |
Entity Address, Address Line One | 13 Gad Feinstein Street |
Entity Address, Address Line Two | Park Rehovot |
Entity Address, Country | IL |
Entity Address, City or Town | Rehovot |
Entity Address, Postal Zip Code | 7638517 |
CONSOLIDATED INTERIM STATEMENTS
CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION - USD ($) $ in Thousands | Jun. 30, 2024 | Dec. 31, 2023 |
CURRENT ASSETS: | ||
Cash and cash equivalents | $ 9,484 | $ 20,772 |
Short-term bank deposits | 11,424 | 10,291 |
Trade receivables | 376 | 357 |
Other receivables and prepaid expenses | 3,696 | 2,973 |
Inventories | 794 | 76 |
Total current assets | 25,774 | 34,469 |
LONG-TERM ASSETS: | ||
Long-term deposits and other receivables | 30 | 28 |
Investment accounted for using the equity method | 100 | 0 |
Right-of-use-assets | 729 | 980 |
Property, plant and equipment, net | 1,650 | 2,455 |
Intangible assets, net | 12,685 | 13,169 |
Total long term assets | 15,194 | 16,632 |
Total assets | 40,968 | 51,101 |
CURRENT LIABILITIES: | ||
Trade payables | 957 | 1,785 |
Employees and payroll accruals | 2,333 | 2,537 |
Lease liability | 558 | 853 |
Liabilities in respect of government grants | 681 | 388 |
Deferred revenues and other advances | 548 | 362 |
Convertible SAFE | 10,392 | 0 |
Other payables | 816 | 1,019 |
Total current liabilities | 16,285 | 6,944 |
LONG-TERM LIABILITIES: | ||
Lease liability | 252 | 285 |
Liabilities in respect of government grants | 4,247 | 4,426 |
Deferred revenues and other advances | 244 | 393 |
Convertible SAFE | 0 | 10,368 |
Total non-current liabilities | 4,743 | 15,472 |
SHAREHOLDERS' EQUITY: | ||
Ordinary shares of NIS 0.2 par value: Authorized -15,000,000 ordinary shares; Issued and outstanding – 5,096,760 shares as of June 30, 2024 and 5,079,313 (*) shares as of December 31, 2023 | 287 | 286 |
Share premium and other capital reserve | 269,648 | 269,353 |
Accumulated deficit | (266,868) | (257,586) |
Equity attributable to equity holders of the Company | 3,067 | 12,053 |
Non-controlling interests | 16,873 | 16,632 |
Total equity | 19,940 | 28,685 |
Shareholder's Equity and Liabilities | $ 40,968 | $ 51,101 |
CONSOLIDATED INTERIM STATEMEN_2
CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION (Parenthetical) - ₪ / shares | Jun. 30, 2024 | Dec. 31, 2023 | |
Statement of financial position [abstract] | |||
Ordinary shares, par value | ₪ 0.2 | ₪ 0.2 | |
Ordinary shares, authorized shares | 15,000,000 | 15,000,000 | |
Ordinary shares, issued shares | 5,096,760 | 5,079,313 | |
Ordinary shares, outstanding shares | 5,096,760 | 5,079,313 | [1] |
[1]Shares and per shares amounts have been retroactively adjusted to reflect the reverse stock split. See Note 9a. |
CONSOLIDATED INRERIM STATEMENTS
CONSOLIDATED INRERIM STATEMENTS OF PROFIT OR LOSS (Unaudited) - USD ($) $ in Thousands | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | ||
Profit or loss [abstract] | |||
Revenue | $ 5,104 | $ 1,295 | |
Cost of revenues | 847 | 783 | |
Gross profit | 4,257 | 512 | |
Operating expenses: | |||
Research and development, net | 8,817 | 10,169 | |
Sales and marketing | 1,920 | 1,728 | |
General and administrative | 3,184 | 3,312 | |
Other expenses | 524 | 0 | |
Total operating expenses, net | 14,445 | 15,209 | |
Operating loss | (10,188) | (14,697) | |
Financing income | 667 | 699 | |
Financing expenses | (288) | (785) | |
Financing income (expenses), net | 379 | (86) | |
Share of loss of an associate | (20) | 0 | |
Loss before taxes on income | (9,829) | (14,783) | |
Taxes on income (tax benefit) | 1 | (24) | |
Loss | (9,830) | (14,759) | |
Attributable to: | |||
Equity holders of the Company | (9,282) | (13,294) | |
Non-controlling interests | (548) | (1,465) | |
Loss | $ (9,830) | $ (14,759) | |
Basic loss per share, attributable to equity holders of the Company | [1] | $ (1.82) | $ (3.18) |
Diluted loss per share, attributable to equity holders of the Company | $ (1.82) | $ (3.18) | |
Weighted average number of ordinary shares used in computing basic loss per share | [1] | 5,087,029 | 4,177,554 |
Weighted average number of ordinary shares used in computing diluted loss per share | 5,087,029 | 4,177,554 | |
[1]Shares and per share amounts have been retroactively adjusted to reflect the reverse stock split. See Note 9a. |
CONSOLIDATED INRERIM STATEMEN_2
CONSOLIDATED INRERIM STATEMENTS OF CHANGES IN EQUITY (Unaudited) - USD ($) $ in Thousands | Share capital | Share premium and other capital reserves | Accumulated deficit | Total Attributable to equity holders of the Company | Non-controlling interests | Total | ||||
Balance at Dec. 31, 2022 | $ 235 | $ 261,402 | $ (233,707) | $ 27,930 | $ 6,860 | $ 34,790 | ||||
Loss | 0 | 0 | (13,294) | (13,294) | (1,465) | (14,759) | ||||
Issuance of ordinary shares, net of issuance expenses | 2 | 334 | 0 | 336 | 0 | 336 | ||||
Forfeiture of non-controlling interests regarding share-based compensation | 0 | 69 | 0 | 69 | (69) | 0 | ||||
Issuance of a subsidiary ordinary shares to the Company | 0 | (809) | 0 | (809) | 809 | 0 | ||||
Issuance of a subsidiary preferred shares to non-controlling interests | 0 | (238) | 0 | (238) | 9,761 | 9,523 | ||||
Restricted stock units (“RSUs”) vested | [1] | [1] | 0 | [1] | 0 | [1] | ||||
Share-based compensation | 0 | 294 | 0 | 294 | 925 | 1,219 | ||||
Balance at Jun. 30, 2023 | 237 | 261,052 | (247,001) | 14,288 | 16,821 | 31,109 | ||||
Balance at Dec. 31, 2023 | 286 | 269,353 | (257,586) | 12,053 | 16,632 | 28,685 | ||||
Loss | 0 | 0 | (9,282) | (9,282) | (548) | (9,830) | ||||
Issuance of ordinary shares, net of issuance expenses | 1 | 85 | 0 | 86 | 0 | 86 | ||||
Forfeiture of non-controlling interests regarding share-based compensation | 0 | 22 | 0 | 22 | (22) | 0 | ||||
Restricted stock units (“RSUs”) vested | [1] | [1] | 0 | [1] | 0 | [1] | ||||
Share-based compensation and RSUs | 0 | 188 | 0 | 188 | 811 | 999 | ||||
Balance at Jun. 30, 2024 | $ 287 | $ 269,648 | $ (266,868) | $ 3,067 | $ 16,873 | $ 19,940 | ||||
[1]Represents an amount lower than $1. |
CONSOLIDATED INRERIM STATEMEN_3
CONSOLIDATED INRERIM STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2024 | Jun. 30, 2023 | |
Cash flows from operating activities | ||
Loss | $ (9,830) | $ (14,759) |
Adjustments to the profit or loss items: | ||
Depreciation | 800 | 807 |
Amortization of intangible assets | 484 | 481 |
Share-based compensation | 999 | 1,219 |
Revaluation of convertible SAFE | 24 | 220 |
Net financing expenses (income) | (222) | 6 |
Loss (gain) from sale of property, plant and equipment | 524 | (26) |
Share of loss of an associate | 20 | 0 |
Taxes on income (tax benefit) | 1 | (24) |
Adjustments to the profit or loss items | 2,630 | 2,683 |
Changes in asset and liability items: | ||
Decrease (increase) in trade receivables | (19) | 170 |
Decrease (increase) in other receivables | (725) | 84 |
Decrease (increase) in inventories | (718) | 317 |
Increase (decrease) in trade payables | (762) | 26 |
Increase (decrease) in employees and payroll accruals | (204) | 172 |
Decrease in other payables | (214) | (162) |
Decrease in deferred revenues and other advances | (84) | (73) |
Changes in asset and liability items | (2,726) | 534 |
Cash received (paid) during the period for: | ||
Interest received | 402 | 283 |
Interest paid | (41) | (66) |
Taxes paid | 0 | (10) |
Net cash used in operating activities | (9,565) | (11,335) |
Cash flows from investing activities: | ||
Purchase of property, plant and equipment | (172) | (483) |
Proceeds from sale of marketable securities | 0 | 6,924 |
Purchase of marketable securities | 0 | (503) |
Proceeds from sale of property, plant and equipment | 10 | 26 |
Investment in short term bank deposits, net | (990) | (13,560) |
Net cash used in investing activities | (1,152) | (7,596) |
Cash flows from financing activities: | ||
Issuance of a subsidiary preferred shares to non-controlling interests | 0 | 9,523 |
Proceeds from issuance of ordinary shares, net of issuance expenses | 86 | 336 |
Repayment of lease liability | (462) | (413) |
Proceeds from government and other grants | 0 | 1,089 |
Repayment of government grants | (142) | (35) |
Net cash provided by (used in) financing activities | (518) | 10,500 |
Exchange rate differences - cash and cash equivalent balances | (53) | (316) |
Decrease in cash and cash equivalents | (11,288) | (8,747) |
Cash and cash equivalents, beginning of the period | 20,772 | 28,980 |
Cash and cash equivalents, end of the period | 9,484 | 20,233 |
Significant non-cash activities | ||
Acquisition of property, plant and equipment, net | 15 | 90 |
Investment in affiliated Company with corresponding deferred revenues | 120 | 0 |
Increase of right-of-use asset recognized with corresponding lease liability | $ 184 | $ 135 |
GENERAL
GENERAL | 6 Months Ended |
Jun. 30, 2024 | |
Disclosure Of General Information [Abstract] | |
GENERAL | NOTE 1: - GENERAL a. Evogene Ltd. (“Evogene” and together with its subsidiaries, the “Company”) was founded on October 10, 1999, as Agro Leads Ltd., a division of Compugen Ltd. In 2002, the Company was spun-off as an independent corporation under the laws of the State of Israel, and changed its name to Evogene Ltd. Evogene is a computational biology company aiming to revolutionize the development of life-science based products by utilizing cutting edge technologies to increase the probability of success while reducing development time and cost. Evogene established three unique tech-engines - MicroBoost AI ChemPass AI GeneRator AI MicroBoost AI ChemPass AI GeneRator AI Evogene uses its tech-engines to develop products through subsidiaries and strategic partnerships. Evogene’s subsidiaries currently utilize the tech-engines to develop human microbiome-based therapeutics by Biomica Ltd., ag-biologicals by Lavie Bio Ltd., ag-chemicals by AgPlenus Ltd. and castor varieties, for the biofuel and other industries, by Casterra Ag Ltd. On April 2, 2024, the Company and The Kitchen FoodTech Hub (TKH), the foodtech incubator and investment arm of Strauss Group, jointly announced the establishment of Finally Foods Ltd., an AI-driven company specializing in molecular farming for the food sector, committed to providing sustainable alternative sources to animal-based proteins. Finally Foods will leverage the Company’s AI technology to modify plants for efficient protein production. Evogene holds approximately 40% of the share capital of Finally Foods, on a fully diluted basis and accounts for this investment using the equity method. The Company has a history of losses and incurred operating losses of $10,188 and $14,697 during the six month periods ended June 30, 2024 and 2023, respectively. Furthermore, the Company intends to continue to finance its operating activities by raising capital and seeking collaborations with multinational companies in the industry and by the operation of castor seeds. The Company's management and board of directors are of the opinion that the Company’s current financial resources and the expected resources from the castor operation will be sufficient to continue the development of the Company's operation in the foreseeable future. b. The Company principally derives its revenues from collaboration arrangements and castor operation. For revenues from major customers see Note 8d. c. The Company has the following subsidiaries: Casterra Ag Ltd. (formerly Evofuel Ltd.), Evogene Inc., Biomica Ltd., AgPlenus Ltd., AgPlenus Inc., Lavie Bio Ltd., Lavie Bio Inc., Lavie Bio Tech Inc., Taxon Biosciences, Inc. and Canonic Ltd. Casterra Ag Ltd. was incorporated on December 29, 2011 and is currently focused on the development of improved castor bean seeds for industrial uses. Evogene Inc. was incorporated in Delaware, United States on September 22, 2006. Evogene Inc. was engaged in research and development in the field of insect control and located in the Bio-Research and Development Growth (BRDG) Park, in St. Louis, Missouri, United States. Biomica Ltd. (“Biomica”) was incorporated on March 2, 2017, with the mission of discovering and developing human microbiome-based therapeutics. AgPlenus Ltd. was incorporated on June 10, 2018, with the mission to design effective and sustainable crop protection ag-chemicals products by leveraging predictive biology. On August 27, 2020, AgPlenus Ltd. incorporated a wholly owned U.S. subsidiary, AgPlenus Inc. Lavie Bio Ltd. was incorporated on January 21, 2019, with the mission to improve food quality and sustainability through the introduction of microbiome-based ag-biologicals products. In 2019, Lavie Bio Ltd. incorporated two wholly owned subsidiaries, Lavie Bio Inc., located in the Bio-Research and Development Growth (BRDG) Park, in St. Louis, Missouri, United States, and Lavie Bio Tech Inc. Lavie Bio Tech Inc. wholly owns as a subsidiary Taxon Biosciences, Inc. (see item d below). Canonic Ltd. was incorporated on March 25, 2019, with the mission of developing next-generation medical cannabis products. During 2024, Canonic Ltd. ceased its operations. d. On August 6, 2019, Corteva Inc. (“Corteva”) invested in the Company's agriculture biologicals subsidiary, Lavie Bio Ltd., which included a cash investment of $10,000 and the contribution of all shares of Corteva’s wholly owned subsidiary Taxon Biosciences, Inc. for 27.84% of Lavie Bio Ltd.'s shares. As part of the foregoing transaction, the parties entered into a commercial arrangement with respect to the commercialization by Corteva of Lavie Bio Ltd.’s products, mainly in corn and soybean. In August 2022, an affiliate company of ICL and Lavie Bio Ltd. entered a multi-year collaboration agreement for developing novel bio-stimulant products to enrich fertilizer efficiency. As part of the collaboration, ICL invested through an affiliate company in Lavie Bio Ltd. $10,000 under a SAFE agreement (simple agreement for future equity). On December 21, 2022, Biomica, signed a definitive agreement for a $20,000 financing round, led by Shanghai Healthcare Capital (“SHC”), out of which $10,000 was to be invested by Evogene in Biomica’s preferred shares. As a result, Evogene recorded a negative capital reserve and an increase of non-controlling interest in the amounts of $238 and $9,761, respectively. In addition, certain convertible loans in total amount of $10,000 were converted by Evogene to Biomica’s ordinary shares. As a result, Evogene recorded an adjustment to capital reserve and non-controlling interest in amount of $809. Following the closing of the transaction on April 25, 2023, Evogene was diluted to approximately 67% of the share capital of Biomica, on a fully diluted basis, while SHC held approximately 20%, on a fully diluted basis. In June 2023, Casterra Ag Ltd. signed a framework agreement with a leading oil and gas energy company for the sale of castor varieties at a commercial scale for biofuel production (the “agreement”). Under the framework of the agreement, during June 2023, Casterra Ag Ltd. received an order totalling $9,100. In addition, during June 2023 Casterra Ag Ltd. received an additional order totalling approximately $2,200 to supply castor seeds. On June 25, 2024, Casterra Ag Ltd. received an additional purchase order totaling approximately $440 to supply castor seeds to a new African country in 2024. e. In January 2021, the Company entered into a Controlled Equity Offering Sales Agreement, pursuant to which the Company issued 380,359 ordinary shares during January and February 2021, in an at-the-market (“ATM”) offering, with a weighted average selling price of $73.6 per share, resulting in gross proceeds of approximately $28,000. On February 19, 2021, the Company entered into a new Controlled Equity Offering Sales Agreement, having an aggregate offering price of up to $50,000 (subsequently reduced to approximately $19,500), pursuant to which the Company issued 72,683 ordinary shares from April through September 2021, in an ATM offering, with a weighted average selling price of $36.4 per share, resulting in gross proceeds of approximately $2,600. During December 2022, 2,851 ordinary shares were issued through the ATM offering, with a weighted selling price of $7.7 per share, resulting in gross proceeds of approximately $22. During 2023, 72,022 ordinary shares were issued through the ATM offering, with a weighted selling price of $9.6 per share, resulting in gross proceeds of approximately $695. During January 2024, 320 ordinary shares were issued through the ATM offering, with a selling price of $10 per share, resulting in gross proceeds of approximately $3. All shares and weighted average selling price amounts mentioned above have been retroactively adjusted to reflect the reverse share split. See also Note 9a. f. On July 17, 2023, the Company entered into securities purchase agreements with certain institutional investors for the sale of 850,000 ordinary shares in a registered direct offering at a purchase price of $10.0 per ordinary share (the “offering”). The gross proceeds from the offering amounted to approximately $8,500, before deducting placement agent fees and other offering expenses. Shares and purchase price amounts mentioned above have been retroactively adjusted to reflect the reverse share split. See also Note 9a. g. On March 1, 2024, the Company filed a shelf registration statement on Form F-3 with the SEC under which the Company may offer and sell from time to time in one or more offerings, the Company’s ordinary shares, rights, warrants and units having an aggregate offering price of up to $200 million. h. On March 28 2024, the Company entered a new At-The-Market Issuance Sales Agreement (the “Sales Agreement”), with Lake Street Capital Markets, LLC as selling agent. In accordance with the terms of the Sales Agreement, from time to time the Company may offer and sell its ordinary shares in an ATM offering having an aggregate offering price of up to $7,300. On August 26, 2024 the aggregate offering price was reduced to up to US$4,500. During May 2024, the Company issued 10,000 ordinary shares pursuant to the Sales Agreement, with a selling price of $8.5 per share, resulting in gross proceeds of approximately $85. i. The Company’s subsidiaries and divisions are split into three operating segments: (1) Agriculture – Evogene Ltd.’s collaborations, Lavie Bio Ltd. and Ag Plenus Ltd.; (2) Human – Biomica Ltd. and Canonic Ltd.; and (3) Industrial – Casterra Ag Ltd. (See also Note 8). |
SIGNIFICANT ACCOUNTING POLICIES
SIGNIFICANT ACCOUNTING POLICIES | 6 Months Ended |
Jun. 30, 2024 | |
Disclosure of significant accounting policies [Abstract] | |
SIGNIFICANT ACCOUNTING POLICIES | NOTE 2: - SIGNIFICANT ACCOUNTING POLICIES Basis of preparation of the interim consolidated financial statements: The interim consolidated financial statements for the six months ended June 30, 2024 have been prepared in accordance with International Accounting Standard 34, “Interim Financial Reporting.” These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended December 31, 2023, included in the Company’s Annual Report on Form 20-F filed with the Securities and Exchange Commission (the “SEC”) on March 28, 2024. The accompanying consolidated balance sheet as of June 30, 2024, the consolidated statements of profit or loss, the consolidated statement of changes in shareholders’ equity and the consolidated statements of cash flows for the six months ended June 30, 2024 and 2023 are unaudited. These unaudited interim consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and applicable rules and regulations of the SEC regarding interim financial reporting. In management’s opinion, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair presentation of the Company’s financial position as of June 30, 2024 and December 31, 2023, as well as its results of operations and cash flows for the six months ended June 30, 2024 and 2023. The results of operations for the six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024. The significant accounting policies applied in the preparation of the interim consolidated financial statements are consistent with those followed in the preparation of the 2023 annual consolidated financial statements. IFRS 18, Presentation and disclosure in Financial Statements In April 2024, the International Accounting Standards Board (“IASB”) issued International Financial Reporting Standard (“IFRS”) 18, Presentation and disclosure in Financial Statements, which replaces International Accounting Standard (“IAS”)1, Presentation of Financial Statements. The new standard is a result of the IASB’s Primary Financial Statements project, which is aimed at improving comparability and transparency of communication in financial statements. While a number of sections have been brought forward from IAS 1, with limited wording changes, IFRS 18 introduces new requirements on presentation within the statement of profit or loss, including the specified totals and subtotals. It also requires disclosure of management defined performance measures and includes new requirements for aggregation and disaggregation of financial information. In addition, certain amendments have been made to IAS 7, Statements of Cash flows. IFRS 18, and the amendments to the other standards, is effective for reporting periods beginning on or after January 1, 2027, but earlier application is permitted and must be disclosed. |
REVENUE FROM CONTRACTS WITH CUS
REVENUE FROM CONTRACTS WITH CUSTOMERS | 6 Months Ended |
Jun. 30, 2024 | |
Disclosure Of Revenue From Contracts With Customers [Abstract] | |
REVENUE FROM CONTRACTS WITH CUSTOMERS | NOTE 3: - REVENUE FROM CONTRACTS WITH CUSTOMERS Disaggregation of revenue The following table disaggregates Company’s revenues by timing of revenue recognition: Six months ended June 30, 2024 2023 Unaudited Revenue recognized at a point in time $ 3,849 $ 496 Revenue recognized over time 1,255 799 $ 5,104 $ 1,295 |
OTHER RECEIVABLES AND PREPAID E
OTHER RECEIVABLES AND PREPAID EXPENSES | 6 Months Ended |
Jun. 30, 2024 | |
Disclosure Of Other Accounts Receivables Abstract | |
OTHER RECEIVABLES AND PREPAID EXPENSES | NOTE 4: - OTHER RECEIVABLES AND PREPAID EXPENSES June 30, 2024 December 31, 2023 Government authorities $ 236 $ 226 Grant receivables - 88 Prepaid expenses 851 909 Suppliers advances (*) 2,294 1,617 Other 315 133 $ 3,696 $ 2,973 (*) As of June 30, 2024, and December 31, 2023, the balance reflects the estimated realization of the suppliers advances of $2,294 and $1,524, respectively, pertaining to the expected value of services from castor seed growing service providers for Casterra Ag Ltd. The estimation of potentially non-recoverable advances takes into account factors such as the supplier’s geographic location, the age of the advance balance, the supplier’s financial condition, and the Company’s past experience with suppliers in similar areas. |
LIABILITIES IN RESPECT OF GOVER
LIABILITIES IN RESPECT OF GOVERNMENT GRANTS | 6 Months Ended |
Jun. 30, 2024 | |
Disclosure Of Liabilities In Respect Of Government Grants [Abstract] | |
LIABILITIES IN RESPECT OF GOVERNMENT GRANTS | NOTE 5: - LIABILITIES IN RESPECT OF GOVERNMENT GRANTS June 30, 2024 December 31, 2023 Unaudited Audited Balance at January 1, $ 4,814 $ 4,744 Grants received or to be received 74 66 Royalties paid (142 ) (73 ) Amounts recorded in profit or loss 182 77 $ 4,928 $ 4,814 The Company received research and development grants from the Israel Innovation Authority (“IIA”) and undertook to pay royalties of 3%-4% of revenues derived from research and development projects that were financed by the IIA, of up to 100% of the grants received (including accrued interest). As of June 30, 2024, the Company had received accumulative grants amounting to $9,223 (including accrued interest), of which $3,741 were repaid to date. |
FINANCIAL INSTRUMENTS
FINANCIAL INSTRUMENTS | 6 Months Ended |
Jun. 30, 2024 | |
Disclosure of detailed information about financial instruments [abstract] | |
FINANCIAL INSTRUMENTS | NOTE 6: - FINANCIAL INSTRUMENTS The carrying amounts of cash and cash equivalents, short-term investments, other receivables, trade payables and other payables approximate their fair values due to the short-term maturities of such instruments. The fair value of the liabilities in respect of government grants is measured using a discount rate that reflects the applicable market rate of interest at the date the grants are received, which approximates the fair value at the respective balance sheet date. The fair value of lease liability is measured using a discount rate that reflects the IBR of interest at the date of the contract. The fair value measurement of the SAFE agreement is based on the weighted average value of various scenarios regarding Lavie Bio Ltd.’s estimated enterprise value at the valuation date. The fair value of the ordinary shares of Lavie Bio Ltd. is measured using the income approach, whereby the expected cash flows generated by Lavie Bio Ltd. are discounted to their present value equivalent using a rate of return that reflects its relative risk, as well as the time value of the money, and is considered to be Level 3 fair value hierarchy. |
SHARE- BASED COMPENSATION
SHARE- BASED COMPENSATION | 6 Months Ended |
Jun. 30, 2024 | |
Disclosure of terms and conditions of share-based payment arrangement [abstract] | |
SHARE- BASED COMPENSATION | NOTE 7: - SHARE- BASED COMPENSATION a. Expenses recognized in the financial statements: The expense recognized in the Company's financial statements for services provided by employees and service-providers is as follows: Six months ended June 30, 2024 2023 Unaudited Share-based compensation - Attributable to equity holders of the Company $ 188 $ 294 Share-based compensation - Attributable to non-controlling interests 811 925 $ 999 $ 1,219 Evogene maintains two share option and equity incentive plans: the Evogene Ltd. 2013 Share Option Plan and the Evogene Ltd. 2021 Share Incentive Plan (the “2021 Plan”). All such option and incentive plans provide for the grant of options to purchase the Company's ordinary shares which generally expire 10 years from the grant date. b. Evogene share-based payment plan for employees, directors and consultants: During the six months ended June 30, 2024 and 2023, the board of directors of Evogene approved to grant to its employees, directors and consultants an aggregate of 13,300 and 47,100 options, respectively. The fair value of the options determined at their grant date using the binomial model was approximately $41 and $153, respectively. c. Evogene share options activity: The following table summarizes the number of share options, the weighted average exercise price, and changes to the number of outstanding options held by employees, consultants and directors of Evogene under the applicable plans, as of June 30, 2024 and June 30, 2023 and over the course of the periods then ended: 2024 (*) 2023 (*) Number of options Weighted average exercise prices ($) Number of options Weighted average exercise prices ($) Outstanding on January 1, 397,452 28.8 403,602 41.7 Granted 13,300 7.0 47,100 7.1 Exercised - - - - Forfeited/Expired (2,938 ) 121.1 (36,211 ) 42.4 Outstanding on June 30, 407,814 26.5 414,491 35.7 Exercisable at June 30, 314,648 30.7 275,770 46.8 ( ) d. Evogene RSUs activity: The 2021 Plan also provides for the grant of restricted shares and RSUs. During the six months ended June 30, 2024 and 2023, the board of directors of the Company approved to grant to the Company's employees an aggregate of 1,300 and 33,260 RSUs, respectively. The fair value of the RSUs granted during the six months ended June 30, 2024 and 2023, was approximately $13 and $249, respectively, determined at their grant date according to Evogene’s share price at the time of their grant since the RSUs were granted at a zero exercise price and no dividends were expected to be distributed during their vesting period. The following table summarizes the number of RSUs, the weighted average grant date fair value and the changes to the number of outstanding RSUs held by employees, consultants and directors of Evogene under the 2021 Plan as of June 30, 2024 and June 30, 2023 and during the periods then ended: 2024 (*) 2023 (*) Number of RSUs Weighted average grant date fair value Number of RSUs Weighted average grant date fair value Outstanding on January 1, 41,420 12.4 19,658 25.5 Granted 1,300 9.7 33,260 7.5 Vested (7,127 ) 14.8 (3,153 ) 26.1 Forfeited/Expired (112 ) 7.5 (1,200 ) 30.4 Outstanding on June 30, 35,481 11.8 48,565 13.0 ( ) e. Evogene’s subsidiaries maintain share option and incentive plans with similar terms and conditions. During the six months ended June 30, 2024 and 2023, Evogene’s subsidiaries approved to grant their employees, directors and consultants 138,500 and 546,839 options, respectively. The fair value of the options determined at their grant date using the binomial model was approximately $974 and $1,601, respectively. The fair value was estimated using the binomial model. The following table summarizes the number of share options, the weighted average exercise price, and the changes to the number of outstanding options held by employees, consultants and directors of Evogene’s subsidiaries under the subsidiary option plans as of June 30, 2024 and June 30, 2023 and during the periods then ended: 2024 2023 Number of options Weighted average exercise prices ($) Number of options Weighted average exercise prices ($) Outstanding on January 1, 2,531,134 1.63 2,273,489 1.72 Granted 138,500 1.46 546,839 1.87 Exercised (5,000 ) 0.19 - - Forfeited/Expired (748,576 ) 0.21 (473,932 ) 3.15 Outstanding on June 30, 1,916,058 2.17 2,346,396 1.46 Exercisable at June 30, 1,037,638 2.01 1,390,561 0.94 f. The total compensation cost related to all of the Company's equity-based awards, recognized during the presented periods was comprised as follows: Six months ended June 30, 2024 2023 Unaudited Cost of revenues $ 15 $ - Research and development, net 232 469 Sales and marketing 345 297 General and administrative 407 453 $ 999 $ 1,219 |
OPERATING SEGMENTS
OPERATING SEGMENTS | 6 Months Ended |
Jun. 30, 2024 | |
Disclosure of operating segments [abstract] | |
OPERATING SEGMENTS | NOTE 8: - OPERATING SEGMENTS a. General: The Company operates in three segments, Agriculture, Industry and Human. The Agriculture segment consists of the parent company, Evogene, and two of Evogene’s subsidiaries, Lavie Bio Ltd. and AgPlenus Ltd. The Human segment consists of Evogene’s subsidiaries, Biomica Ltd. and Canonic Ltd. The Industry segment consists of Evogene’s subsidiary Casterra Ag Ltd. The segments were determined on the basis of information considered by the Chief Operating Decision-Maker (“CODM”) for purposes of decision-making on the allocation of resources and evaluation of performance. The following Company's segments are engaged in business activities for which they earn revenues and incur expenses, their results are reviewed by the CODM and discrete financial information is available: Agriculture segment - Develops seed traits, ag-chemical products, and ag-biological products to improve plant performance. Industry segment - Develops improved castor bean seeds to serve as a feedstock source for other industrial uses. Human segment - Discovery and development of human microbiome-based therapeutics and cannabis activity. Unallocated - Other corporate expenses and general development of enabling technologies for optimization. Each segment’s performance is determined based on operating loss reported in the financial statements. The results of a segment reported to the CODM include items attributed directly to a segment, as well as other items, which are indirectly attributed using reasonable assumptions. b. The following table presents the Company’s revenues and operating loss by segments: Agriculture Industry Human Unallocated Total Unaudited For the six months ended June 30, 2024 Revenues $ 4,648 $ 196 $ 77 $ 183 $ 5,104 Operating loss $ (3,104 ) $ (1,225 ) $ (4,000 ) $ (1,859 ) $ (10,188 ) Net financing income $ 379 Share of loss of an associate $ (20 ) Loss before taxes on income $ (9,829 ) c. The following table presents the Company’s revenues and operating loss by segments: Agriculture Industry Human Unallocated Total Unaudited For the six months ended June 30, 2023 Revenues $ 819 $ 28 $ 300 $ 148 $ 1,295 Operating loss $ (5,751 ) $ (156 ) $ (4,795 ) $ (3,995 ) $ (14,697 ) Net financing expenses $ (86 ) Loss before taxes on income $ (14,783 ) d. Major customers: Detailed below are revenues from major customers each of which accounts for 10% or more, of total revenues. The revenues from major customers detailed below were recorded in the Agriculture segment: Six months ended June 30, 2024 2023 Unaudited Customer A (shareholder of a subsidiary) 58 % 49 % Customer B - 22 % Customer C - 12 % Customer D 26 % - e. Major contracts with customers: During the six months ended June 30, 2023, the Company did not enter into any collaboration agreements which amount to 10% or more of its total revenues for the period ended June 30, 2023. During the second half of 2023 and during the six months ended June 30, 2024, the Company entered into several collaboration agreements which amount to 10% or more of its total revenues for the six months ended June 30, 2024: (i) During July 2023, Lavie Bio Ltd. entered into a licensing agreement with Corteva, conferring exclusive rights to Corteva for advancing and commercializing Lavie Bio's lead bio-fungicides, LAV311 and LAV312. Lavie Bio Ltd. received an initial payment of $5,000, in two installments, a first payment of $2,500 was received during September 2023. In March 2024, Lavie Bio Ltd. received the second payment of $2,500. In addition, Lavie Bio Ltd. will also be eligible for additional future milestone payments and royalties from Corteva's sales of the products. (ii) On February 16, 2024, AgPlenus Ltd. entered into a Licensing and Collaboration Agreement (“the Agreement”) with Bayer AG (“Bayer”) for the development of a new sustainable weed control solution. This agreement grants Bayer an exclusive license for the development and commercialization of products developed within the collaboration. According to the Agreement AgPlenus will be entitled to receive a license payment, ongoing research funding, milestone payments, and royalties based on future product sales, subject to certain conditions as stipulated in the Agreement. f. Geographical information: Revenues based on the location of the customers, are as follows: Six months ended June 30, 2024 2023 Unaudited United States 64 % 62 % Europe 27 % - Israel 6 % 36 % Africa 3 % 2 % 100 % 100 % The carrying amounts of non-current assets (property, plant and equipment property and intangible assets) in Evogene’s country of domicile (Israel) and in the United States based on the location of the assets, are as follows: June 30, 2024 December 31, 2023 Unaudited Audited United States 85 % 80 % Israel 15 % 20 % 100 % 100 % |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 6 Months Ended |
Jun. 30, 2024 | |
Disclosure of non-adjusting events after reporting period [abstract] | |
SUBSEQUENT EVENTS | NOTE 9: - SUBSEQUENT EVENTS a. On July 23, 2024 Evogene announced a reverse share split of its issued and outstanding Ordinary Shares, at a ratio of 1-for-10, which was implemented after market close on July 24, 2024. Evogene’s Ordinary Shares began trading on the Nasdaq Capital Market on a post-reverse split basis at the market open on July 25, 2024, and on the Tel Aviv Stock Exchange at the market open on July 28, 2024. The reverse share split was approved by Evogene’s shareholders at the Company’s Annual Meeting of Shareholders held on June 13, 2024, to be effected at the board of directors’ discretion within approved parameters. In addition, proportionate adjustments were made to the number of shares issuable upon the exercise of all outstanding options entitling the holders to purchase Ordinary Shares (with a reciprocal increase in the per share exercise price) and to the number of Ordinary Shares underlying outstanding Restricted Share Units (RSUs). b. On August 23, 2024, Evogene entered into a definitive securities purchase agreement, or the Securities Purchase Agreement, with an institutional investor, or the Investor, pursuant to which, on August 26, 2024 Evogene issued and sold to such investor in a registered direct offering, or the Offering, (i) 265,000 Ordinary Shares, and (ii) pre-funded warrants, or the Pre-Funded Warrants, to purchase up to 1,427,308 Ordinary Shares. The Pre-Funded Warrants have an exercise price of $0.0001 per Ordinary Share, are immediately exercisable and may be exercised at any time until exercised in full. In a concurrent private placement, the Company also issued to the Investor unregistered Series A ordinary warrants to purchase up to 1,692,308 ordinary shares, and unregistered Series B ordinary warrants to purchase up to 1,692,308 ordinary shares. Each ordinary share (or ordinary share equivalent in lieu thereof) was sold with one Series A ordinary warrant to purchase one ordinary share and one Series B ordinary warrant to purchase one ordinary share at a combined purchase price of US$3.25. The Series A ordinary warrants have an exercise price of US$3.55 per share, immediately exercisable upon issuance and will expire five years from issuance. The Series B ordinary warrants have an exercise price of US$3.55 per share, immediately exercisable upon issuance and will expire eighteen months from issuance. The gross proceeds from the Offering were approximately US$5.5 million before deducting placement agent fees and other offering expenses. |
SIGNIFICANT ACCOUNTING POLICI_2
SIGNIFICANT ACCOUNTING POLICIES (Policies) | 6 Months Ended |
Jun. 30, 2024 | |
Disclosure of significant accounting policies [Abstract] | |
Basis of preparation of the interim consolidated financial statements | Basis of preparation of the interim consolidated financial statements: The interim consolidated financial statements for the six months ended June 30, 2024 have been prepared in accordance with International Accounting Standard 34, “Interim Financial Reporting.” These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended December 31, 2023, included in the Company’s Annual Report on Form 20-F filed with the Securities and Exchange Commission (the “SEC”) on March 28, 2024. The accompanying consolidated balance sheet as of June 30, 2024, the consolidated statements of profit or loss, the consolidated statement of changes in shareholders’ equity and the consolidated statements of cash flows for the six months ended June 30, 2024 and 2023 are unaudited. These unaudited interim consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and applicable rules and regulations of the SEC regarding interim financial reporting. In management’s opinion, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair presentation of the Company’s financial position as of June 30, 2024 and December 31, 2023, as well as its results of operations and cash flows for the six months ended June 30, 2024 and 2023. The results of operations for the six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024. The significant accounting policies applied in the preparation of the interim consolidated financial statements are consistent with those followed in the preparation of the 2023 annual consolidated financial statements. |
IFRS 18, Presentation and disclosure in Financial Statements | IFRS 18, Presentation and disclosure in Financial Statements In April 2024, the International Accounting Standards Board (“IASB”) issued International Financial Reporting Standard (“IFRS”) 18, Presentation and disclosure in Financial Statements, which replaces International Accounting Standard (“IAS”)1, Presentation of Financial Statements. The new standard is a result of the IASB’s Primary Financial Statements project, which is aimed at improving comparability and transparency of communication in financial statements. While a number of sections have been brought forward from IAS 1, with limited wording changes, IFRS 18 introduces new requirements on presentation within the statement of profit or loss, including the specified totals and subtotals. It also requires disclosure of management defined performance measures and includes new requirements for aggregation and disaggregation of financial information. In addition, certain amendments have been made to IAS 7, Statements of Cash flows. IFRS 18, and the amendments to the other standards, is effective for reporting periods beginning on or after January 1, 2027, but earlier application is permitted and must be disclosed. |
REVENUE FROM CONTRACTS WITH C_2
REVENUE FROM CONTRACTS WITH CUSTOMERS (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Disclosure Of Revenue From Contracts With Customers [Abstract] | |
Schedule of revenues by timing of revenue recognition | Six months ended June 30, 2024 2023 Unaudited Revenue recognized at a point in time $ 3,849 $ 496 Revenue recognized over time 1,255 799 $ 5,104 $ 1,295 |
OTHER RECEIVABLES AND PREPAID_2
OTHER RECEIVABLES AND PREPAID EXPENSES (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Disclosure Of Other Accounts Receivables Abstract | |
Schedule of other receivables and prepaid expenses | June 30, 2024 December 31, 2023 Government authorities $ 236 $ 226 Grant receivables - 88 Prepaid expenses 851 909 Suppliers advances (*) 2,294 1,617 Other 315 133 $ 3,696 $ 2,973 (*) As of June 30, 2024, and December 31, 2023, the balance reflects the estimated realization of the suppliers advances of $2,294 and $1,524, respectively, pertaining to the expected value of services from castor seed growing service providers for Casterra Ag Ltd. The estimation of potentially non-recoverable advances takes into account factors such as the supplier’s geographic location, the age of the advance balance, the supplier’s financial condition, and the Company’s past experience with suppliers in similar areas. |
LIABILITIES IN RESPECT OF GOV_2
LIABILITIES IN RESPECT OF GOVERNMENT GRANTS (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Disclosure Of Liabilities In Respect Of Government Grants [Abstract] | |
Schedule of liabilities in respect of government grants | June 30, 2024 December 31, 2023 Unaudited Audited Balance at January 1, $ 4,814 $ 4,744 Grants received or to be received 74 66 Royalties paid (142 ) (73 ) Amounts recorded in profit or loss 182 77 $ 4,928 $ 4,814 |
SHARE- BASED COMPENSATION (Tabl
SHARE- BASED COMPENSATION (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |
Schedule of expense recognized in financial statements | Six months ended June 30, 2024 2023 Unaudited Share-based compensation - Attributable to equity holders of the Company $ 188 $ 294 Share-based compensation - Attributable to non-controlling interests 811 925 $ 999 $ 1,219 |
Schedule of number of Restricted Stock Units (RSU) | 2024 (*) 2023 (*) Number of RSUs Weighted average grant date fair value Number of RSUs Weighted average grant date fair value Outstanding on January 1, 41,420 12.4 19,658 25.5 Granted 1,300 9.7 33,260 7.5 Vested (7,127 ) 14.8 (3,153 ) 26.1 Forfeited/Expired (112 ) 7.5 (1,200 ) 30.4 Outstanding on June 30, 35,481 11.8 48,565 13.0 ( ) |
Schedule of compensation cost of equity-based awards | Six months ended June 30, 2024 2023 Unaudited Cost of revenues $ 15 $ - Research and development, net 232 469 Sales and marketing 345 297 General and administrative 407 453 $ 999 $ 1,219 |
Employees, consultants and directors | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |
Schedule of number of share options | 2024 (*) 2023 (*) Number of options Weighted average exercise prices ($) Number of options Weighted average exercise prices ($) Outstanding on January 1, 397,452 28.8 403,602 41.7 Granted 13,300 7.0 47,100 7.1 Exercised - - - - Forfeited/Expired (2,938 ) 121.1 (36,211 ) 42.4 Outstanding on June 30, 407,814 26.5 414,491 35.7 Exercisable at June 30, 314,648 30.7 275,770 46.8 ( ) |
Employees, consultants and directors of company's subsidiaries | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |
Schedule of number of share options | 2024 2023 Number of options Weighted average exercise prices ($) Number of options Weighted average exercise prices ($) Outstanding on January 1, 2,531,134 1.63 2,273,489 1.72 Granted 138,500 1.46 546,839 1.87 Exercised (5,000 ) 0.19 - - Forfeited/Expired (748,576 ) 0.21 (473,932 ) 3.15 Outstanding on June 30, 1,916,058 2.17 2,346,396 1.46 Exercisable at June 30, 1,037,638 2.01 1,390,561 0.94 |
OPERATING SEGMENTS (Tables)
OPERATING SEGMENTS (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Disclosure of operating segments [abstract] | |
Schedule of revenues and operating loss by segments | Agriculture Industry Human Unallocated Total Unaudited For the six months ended June 30, 2024 Revenues $ 4,648 $ 196 $ 77 $ 183 $ 5,104 Operating loss $ (3,104 ) $ (1,225 ) $ (4,000 ) $ (1,859 ) $ (10,188 ) Net financing income $ 379 Share of loss of an associate $ (20 ) Loss before taxes on income $ (9,829 ) Agriculture Industry Human Unallocated Total Unaudited For the six months ended June 30, 2023 Revenues $ 819 $ 28 $ 300 $ 148 $ 1,295 Operating loss $ (5,751 ) $ (156 ) $ (4,795 ) $ (3,995 ) $ (14,697 ) Net financing expenses $ (86 ) Loss before taxes on income $ (14,783 ) |
Schedule of major customers | Six months ended June 30, 2024 2023 Unaudited Customer A (shareholder of a subsidiary) 58 % 49 % Customer B - 22 % Customer C - 12 % Customer D 26 % - |
Schedule of geographical information | Six months ended June 30, 2024 2023 Unaudited United States 64 % 62 % Europe 27 % - Israel 6 % 36 % Africa 3 % 2 % 100 % 100 % |
Schedule of percentage of non-current assets | June 30, 2024 December 31, 2023 Unaudited Audited United States 85 % 80 % Israel 15 % 20 % 100 % 100 % |
GENERAL (Narrative) (Details)
GENERAL (Narrative) (Details) $ / shares in Units, $ in Thousands | 1 Months Ended | 6 Months Ended | 12 Months Ended | |||||||||||||||||
Mar. 01, 2024 USD ($) | Aug. 26, 2024 USD ($) | Jun. 30, 2024 USD ($) | May 31, 2024 USD ($) $ / shares shares | Mar. 28, 2024 USD ($) | Jan. 31, 2024 USD ($) $ / shares shares | Jul. 17, 2023 USD ($) $ / shares shares | Jun. 30, 2023 USD ($) | Dec. 31, 2022 USD ($) $ / shares shares | Dec. 21, 2022 USD ($) | Aug. 31, 2022 USD ($) | Apr. 30, 2021 USD ($) $ / shares shares | Feb. 19, 2021 USD ($) | Jan. 31, 2021 USD ($) $ / shares shares | Jun. 30, 2024 USD ($) | Jun. 30, 2023 USD ($) | Dec. 31, 2023 USD ($) $ / shares | Jun. 30, 2024 ₪ / shares shares | Dec. 31, 2023 ₪ / shares shares | Aug. 06, 2019 USD ($) | |
Disclosure of detailed information about business combination [line items] | ||||||||||||||||||||
Operating loss | $ (10,188) | $ (14,697) | ||||||||||||||||||
Number of shares issue | shares | 5,096,760 | 5,079,313 | ||||||||||||||||||
Ordinary shares, par value | ₪ / shares | ₪ 0.2 | ₪ 0.2 | ||||||||||||||||||
Aggregate offering price | $ 200,000 | $ 50,000 | ||||||||||||||||||
Aggregate offering price subsequently reduced | $ 19,500 | |||||||||||||||||||
Issuance of a subsidiary ordinary shares to the Company | 0 | |||||||||||||||||||
Issuance of a subsidiary preferred shares to non-controlling interests | 9,523 | |||||||||||||||||||
Biomica | Definitive Agreement | ||||||||||||||||||||
Disclosure of detailed information about business combination [line items] | ||||||||||||||||||||
Proportion of ownership interest in subsidiary | 67% | |||||||||||||||||||
Finally Foods | ||||||||||||||||||||
Disclosure of detailed information about business combination [line items] | ||||||||||||||||||||
Number of ordinary shares sold | 40% | |||||||||||||||||||
At Market Offering ATM | ||||||||||||||||||||
Disclosure of detailed information about business combination [line items] | ||||||||||||||||||||
Number of shares issue | shares | 10,000 | 320 | 2,851 | 72,683 | 380,359 | 72,022 | ||||||||||||||
Cash inflow from issuing shares | $ 85 | $ 3 | $ 22 | $ 695 | ||||||||||||||||
Ordinary shares, par value | $ / shares | $ 36.4 | $ 73.6 | ||||||||||||||||||
Proceeds from issuing shares | $ 2,600 | $ 28,000 | ||||||||||||||||||
Aggregate offering price | $ 7,300 | |||||||||||||||||||
Aggregate offering price subsequently reduced | $ 4,500 | |||||||||||||||||||
Selling price | $ / shares | $ 8.5 | $ 10 | $ 7.7 | $ 9.6 | ||||||||||||||||
Shanghai Healthcare Capital | Biomica | Definitive Agreement | ||||||||||||||||||||
Disclosure of detailed information about business combination [line items] | ||||||||||||||||||||
Cash investment | $ 10,000 | |||||||||||||||||||
Amount Of Investment In Financing Round | $ 20,000 | |||||||||||||||||||
Proportion of ownership interest in subsidiary | 20% | |||||||||||||||||||
Amount of convertible loans to ordinary shares | $ 10,000 | |||||||||||||||||||
Casterra Ag Ltd | ||||||||||||||||||||
Disclosure of detailed information about business combination [line items] | ||||||||||||||||||||
Expected future sales to supply castor seeds | $ 9,100 | |||||||||||||||||||
Expected additional future sales to supply castor seeds | $ 440 | $ 2,200 | ||||||||||||||||||
Share premium and other capital reserves | ||||||||||||||||||||
Disclosure of detailed information about business combination [line items] | ||||||||||||||||||||
Issuance of a subsidiary ordinary shares to the Company | (809) | |||||||||||||||||||
Issuance of a subsidiary preferred shares to non-controlling interests | (238) | |||||||||||||||||||
Share premium and other capital reserves | Shanghai Healthcare Capital | Biomica | Definitive Agreement | ||||||||||||||||||||
Disclosure of detailed information about business combination [line items] | ||||||||||||||||||||
Issuance of a subsidiary preferred shares to non-controlling interests | 238 | |||||||||||||||||||
Non-controlling Interests | ||||||||||||||||||||
Disclosure of detailed information about business combination [line items] | ||||||||||||||||||||
Issuance of a subsidiary ordinary shares to the Company | 809 | |||||||||||||||||||
Issuance of a subsidiary preferred shares to non-controlling interests | $ 9,761 | |||||||||||||||||||
Non-controlling Interests | Shanghai Healthcare Capital | Biomica | Definitive Agreement | ||||||||||||||||||||
Disclosure of detailed information about business combination [line items] | ||||||||||||||||||||
Issuance of a subsidiary ordinary shares to the Company | 809 | |||||||||||||||||||
Issuance of a subsidiary preferred shares to non-controlling interests | $ 9,761 | |||||||||||||||||||
ATM offering [Member] | ||||||||||||||||||||
Disclosure of detailed information about business combination [line items] | ||||||||||||||||||||
Cash inflow from issuing shares | $ 8,500 | |||||||||||||||||||
Number of ordinary shares sold | shares | 850,000 | |||||||||||||||||||
Purchase price per share | $ / shares | $ 10 | |||||||||||||||||||
Lavie Bio Ltd. | ||||||||||||||||||||
Disclosure of detailed information about business combination [line items] | ||||||||||||||||||||
Cash investment | $ 10,000 | |||||||||||||||||||
Number of ordinary shares sold | 27.84% | |||||||||||||||||||
Lavie Bio Ltd. | ICL Group | ||||||||||||||||||||
Disclosure of detailed information about business combination [line items] | ||||||||||||||||||||
Amount of investment under collaboration agreement | $ 10,000 |
REVENUE FROM CONTRACTS WITH C_3
REVENUE FROM CONTRACTS WITH CUSTOMERS (Schedule of revenues by timing of revenue recognition) (Details) - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2024 | Jun. 30, 2023 | |
Disclosure Of Revenue From Contracts With Customers [Abstract] | ||
Revenue recognized at a point in time | $ 3,849 | $ 496 |
Revenue recognized over time | 1,255 | 799 |
Revenue | $ 5,104 | $ 1,295 |
OTHER RECEIVABLES AND PREPAID_3
OTHER RECEIVABLES AND PREPAID EXPENSES (Narrative) (Details) - USD ($) $ in Thousands | Jun. 30, 2024 | Dec. 31, 2023 |
Disclosure Of Other Accounts Receivables Abstract | ||
Suppliers advances | $ 2,294 | $ 1,524 |
OTHER RECEIVABLES AND PREPAID_4
OTHER RECEIVABLES AND PREPAID EXPENSES (Schedule of Other Receivables and Prepaid Expenses) (Details) - USD ($) $ in Thousands | Jun. 30, 2024 | Dec. 31, 2023 | |
Disclosure Of Other Accounts Receivables Abstract | |||
Government authorities | $ 236 | $ 226 | |
Grant receivables | 0 | 88 | |
Prepaid expenses | 851 | 909 | |
Suppliers advances | [1] | 2,294 | 1,617 |
Other | 315 | 133 | |
Other receivables | $ 3,696 | $ 2,973 | |
[1]As of June 30, 2024, and December 31, 2023, the balance reflects the estimated realization of the suppliers advances of $2,294 and $1,524, respectively, pertaining to the expected value of services from castor seed growing service providers for Casterra Ag Ltd. The estimation of potentially non-recoverable advances takes into account factors such as the supplier’s geographic location, the age of the advance balance, the supplier’s financial condition, and the Company’s past experience with suppliers in similar areas. |
LIABILITIES IN RESPECT OF GOV_3
LIABILITIES IN RESPECT OF GOVERNMENT GRANTS (Narrative) (Details) - IIA [Member] $ in Thousands | 6 Months Ended |
Jun. 30, 2024 USD ($) | |
Disclosure of transactions between related parties [line items] | |
Percentage of royalties paid | 3%-4% of revenues derived from research and development projects |
Maximum percentage for grant received | 100% |
Aggregate Accumulative Grant Received Including Accrued Interest | $ 9,223 |
Aggregate accumulative grant repaid | $ 3,741 |
LIABILITIES IN RESPECT OF GOV_4
LIABILITIES IN RESPECT OF GOVERNMENT GRANTS (Schedule of Liabilities in Respect of Government Grants) (Details) - USD ($) $ in Thousands | 6 Months Ended | 12 Months Ended |
Jun. 30, 2024 | Dec. 31, 2023 | |
Disclosure Of Liabilities In Respect Of Government Grants [Abstract] | ||
Balance at January 1, | $ 4,814 | $ 4,744 |
Grants received or to be received | 74 | 66 |
Royalties paid | (142) | (73) |
Amounts recorded in profit or loss | 182 | 77 |
Ending balance | $ 4,928 | $ 4,814 |
SHARE- BASED COMPENSATION (Narr
SHARE- BASED COMPENSATION (Narrative) (Details) $ in Thousands | 6 Months Ended | ||
Jun. 30, 2024 USD ($) Years shares | Jun. 30, 2023 USD ($) shares | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Share option and incentive plans description | Evogene Ltd. 2013 Share Option Plan and the Evogene Ltd. 2021 Share Incentive Plan (the “2021 Plan”) | ||
Maturity for share option and incentive plans | Years | 10 | ||
Employees Directors And Consultants | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Granted | shares | 13,300 | 47,100 | |
Fair value of options granted | $ | $ 41 | $ 153 | |
Employees, consultants and directors of company's subsidiaries | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Granted | shares | 138,500 | 546,839 | |
Fair value of options granted | $ | $ 974 | $ 1,601 | |
Restricted Stock Units | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Number of RSUs, Granted | shares | [1] | 1,300 | 33,260 |
Fair value of restricted stock units granted | $ | $ 13 | $ 249 | |
[1]Number of RSUs and weighted average grant date fair value have been retroactively adjusted to reflect the reverse share split. See Note 9a. |
SHARE- BASED COMPENSATION (Sche
SHARE- BASED COMPENSATION (Schedule of Company's Financial Statements) (Details) - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2024 | Jun. 30, 2023 | |
Disclosure of terms and conditions of share-based payment arrangement [abstract] | ||
Share-based compensation - Attributable to equity holders of the Company | $ 188 | $ 294 |
Share-based compensation - Attributable to non-controlling interests | 811 | 925 |
Total share-based compensation | $ 999 | $ 1,219 |
SHARE- BASED COMPENSATION (Sc_2
SHARE- BASED COMPENSATION (Schedule of Summarized Number of Share Options) (Details) | 6 Months Ended | ||
Jun. 30, 2024 shares $ / shares | Jun. 30, 2023 shares $ / shares | ||
Employees, consultants and directors | |||
Number [Abstract] | |||
Outstanding at beginning of year | shares | [1] | 397,452 | 403,602 |
Granted | shares | [1] | 13,300 | 47,100 |
Exercised | shares | [1] | 0 | 0 |
Forfeited/Expired | shares | [1] | (2,938) | (36,211) |
Outstanding at end of year | shares | [1] | 407,814 | 414,491 |
Exercisable at end of year | shares | [1] | 314,648 | 275,770 |
Weighted Average Exercise Prices [Abstract] | |||
Weighted average grant date fair value, Outstanding on January 1, | $ / shares | [1] | $ 28.8 | $ 41.7 |
Granted | $ / shares | [1] | 7 | 7.1 |
Exercised | $ / shares | [1] | 0 | 0 |
Forfeited/Expired | $ / shares | [1] | 121.1 | 42.4 |
Weighted average grant date fair value, Outstanding on June 30, | $ / shares | [1] | 26.5 | 35.7 |
Exercisable at end of year | $ / shares | [1] | $ 30.7 | $ 46.8 |
Employees, consultants and directors of company's subsidiaries | |||
Number [Abstract] | |||
Outstanding at beginning of year | shares | 2,531,134 | 2,273,489 | |
Granted | shares | 138,500 | 546,839 | |
Exercised | shares | (5,000) | 0 | |
Forfeited/Expired | shares | (748,576) | (473,932) | |
Outstanding at end of year | shares | 1,916,058 | 2,346,396 | |
Exercisable at end of year | shares | 1,037,638 | 1,390,561 | |
Weighted Average Exercise Prices [Abstract] | |||
Weighted average grant date fair value, Outstanding on January 1, | $ / shares | $ 1.63 | $ 1.72 | |
Granted | $ / shares | 1.46 | 1.87 | |
Exercised | $ / shares | 0.19 | 0 | |
Forfeited/Expired | $ / shares | 0.21 | 3.15 | |
Weighted average grant date fair value, Outstanding on June 30, | $ / shares | 2.17 | 1.46 | |
Exercisable at end of year | $ / shares | $ 2.01 | $ 0.94 | |
[1]Number of options and weighted average exercise prices have been retroactively adjusted to reflect the reverse stock split. See Note 9a. |
SHARE- BASED COMPENSATION (Sc_3
SHARE- BASED COMPENSATION (Schedule of Restricted Stock Units activity) (Details) - Restricted Stock Units | 6 Months Ended | ||
Jun. 30, 2024 shares $ / shares | Jun. 30, 2023 shares $ / shares | ||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Number of RSUs, Outstanding on January 1, | shares | [1] | 41,420 | 19,658 |
Number of RSUs, Granted | shares | [1] | 1,300 | 33,260 |
Number of RSUs, Vested | shares | [1] | (7,127) | (3,153) |
Number of RSUs, Forfeited/Expired | shares | [1] | (112) | (1,200) |
Number of RSUs, Outstanding on June 30, | shares | [1] | 35,481 | 48,565 |
Weighted average grant date fair value, Outstanding on January 1, | $ / shares | [1] | $ 12.4 | $ 25.5 |
Weighted average grant date fair value, Granted | $ / shares | [1] | 9.7 | 7.5 |
Weighted average grant date fair value, Vested | $ / shares | [1] | 14.8 | 26.1 |
Weighted average grant date fair value, Forfeited/Expired | $ / shares | [1] | 7.5 | 30.4 |
Weighted average grant date fair value, Outstanding on June 30, | $ / shares | [1] | $ 11.8 | $ 13 |
[1]Number of RSUs and weighted average grant date fair value have been retroactively adjusted to reflect the reverse share split. See Note 9a. |
SHARE- BASED COMPENSATION (Sc_4
SHARE- BASED COMPENSATION (Schedule of Compensation Cost of Equity-Based Awards) (Details) - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2024 | Jun. 30, 2023 | |
Disclosure of terms and conditions of share-based payment arrangement [abstract] | ||
Cost of revenues | $ 15 | $ 0 |
Research and development, net | 232 | 469 |
Sales and marketing | 345 | 297 |
General and administrative | 407 | 453 |
Total share-based compensation | $ 999 | $ 1,219 |
OPERATING SEGMENTS (Narrative)
OPERATING SEGMENTS (Narrative) (Details) - USD ($) $ in Thousands | 1 Months Ended | 6 Months Ended | ||||
Mar. 31, 2024 | Sep. 30, 2023 | Jul. 31, 2023 | Jun. 30, 2024 | Dec. 31, 2023 | Jun. 30, 2023 | |
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||
Percentage of entitys revenue | 10% | |||||
Percentage of entitys revenue, entered into several collaboration agreements | 10% | 10% | ||||
Lavie Bio Ltd [Member] | ||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||
Initial payment | $ 5,000 | |||||
Lavie Bio Ltd [Member] | First Payment [Member] | ||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||
Initial payment | $ 2,500 | |||||
Lavie Bio Ltd [Member] | Second Payment [Member] | ||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||
Second Payment | $ 2,500 |
OPERATING SEGMENTS (Schedule of
OPERATING SEGMENTS (Schedule of Revenues and Operating Loss by Segments) (Details) - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2024 | Jun. 30, 2023 | |
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Revenue | $ 5,104 | $ 1,295 |
Operating loss | (10,188) | (14,697) |
Net financing expenses | 379 | (86) |
Share of loss of an associate | (20) | |
Loss before taxes on income | (9,829) | (14,783) |
Agriculture | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Revenue | 4,648 | 819 |
Operating loss | (3,104) | (5,751) |
Industry | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Revenue | 196 | 28 |
Operating loss | (1,225) | (156) |
Human | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Revenue | 77 | 300 |
Operating loss | (4,000) | (4,795) |
Unallocated | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Revenue | 183 | 148 |
Operating loss | $ (1,859) | $ (3,995) |
OPERATING SEGMENTS (Schedule _2
OPERATING SEGMENTS (Schedule of Revenues from Major Customers) (Details) | 6 Months Ended | |
Jun. 30, 2024 | Jun. 30, 2023 | |
Disclosure of major customers [line items] | ||
Additional information about revenues | 100% | 100% |
Customer A (shareholder of a subsidiary) | ||
Disclosure of major customers [line items] | ||
Additional information about revenues | 58% | 49% |
Customer B | ||
Disclosure of major customers [line items] | ||
Additional information about revenues | 0% | 22% |
Customer C | ||
Disclosure of major customers [line items] | ||
Additional information about revenues | 0% | 12% |
Customer D | ||
Disclosure of major customers [line items] | ||
Additional information about revenues | 26% | 0% |
OPERATING SEGMENTS (Schedule _3
OPERATING SEGMENTS (Schedule of Revenues Based on Customers) (Details) | 6 Months Ended | |
Jun. 30, 2024 | Jun. 30, 2023 | |
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Revenue | 100% | 100% |
United States | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Revenue | 64% | 62% |
Europe | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Revenue | 27% | 0% |
Israel | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Revenue | 6% | 36% |
Africa | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Revenue | 3% | 2% |
OPERATING SEGMENTS (Schedule _4
OPERATING SEGMENTS (Schedule of Percentage of Non-Current Assets) (Details) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2024 | Dec. 31, 2023 | |
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Non-current assets Percentage | 100% | 100% |
United States | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Non-current assets Percentage | 85% | 80% |
Israel | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Non-current assets Percentage | 15% | 20% |
SUBSEQUENT EVENTS (Narrative) (
SUBSEQUENT EVENTS (Narrative) (Details) $ / shares in Units, $ in Thousands | 6 Months Ended | ||||||
Aug. 23, 2024 USD ($) | Jun. 23, 2024 | Jun. 30, 2024 USD ($) shares | Jun. 30, 2023 USD ($) | Aug. 23, 2024 ₪ / shares shares | Aug. 23, 2024 $ / shares shares | Dec. 31, 2023 shares | |
Disclosure of non-adjusting events after reporting period [line items] | |||||||
Number of shares issue | 5,096,760 | 5,079,313 | |||||
Gross proceeds from the offering | $ | $ 86 | $ 336 | |||||
Subsequent Event | |||||||
Disclosure of non-adjusting events after reporting period [line items] | |||||||
Reverse share split | Evogene announced a reverse share split of its issued and outstanding Ordinary Shares, at a ratio of 1-for-10, which was implemented after market close on July 24, 2024. Evogene’s Ordinary Shares began trading on the Nasdaq Capital Market on a post-reverse split basis at the market open on July 25, 2024, and on the Tel Aviv Stock Exchange at the market open on July 28, 2024. | ||||||
Subsequent Event | Institutional Investor | Definitive Securities Purchase Agreement | |||||||
Disclosure of non-adjusting events after reporting period [line items] | |||||||
Number of shares issue | 265,000 | 265,000 | |||||
Gross proceeds from the offering | $ | $ 5,500 | ||||||
Subsequent Event | Institutional Investor | Definitive Securities Purchase Agreement | Pre-Funded Warrants | |||||||
Disclosure of non-adjusting events after reporting period [line items] | |||||||
Number of warrants issued | 1,427,308 | 1,427,308 | |||||
Exercise price of warrants | ₪ / shares | ₪ 0.0001 | ||||||
Description for warrants | Each ordinary share (or ordinary share equivalent in lieu thereof) was sold with one Series A ordinary warrant to purchase one ordinary share and one Series B ordinary warrant to purchase one ordinary share at a combined purchase price of US$3.25. | ||||||
Subsequent Event | Institutional Investor | Definitive Securities Purchase Agreement | Series A ordinary warrants | |||||||
Disclosure of non-adjusting events after reporting period [line items] | |||||||
Number of warrants issued | 1,692,308 | 1,692,308 | |||||
Exercise price of warrants | $ / shares | $ 3.55 | ||||||
Warrant expiration period | five years from issuance | ||||||
Subsequent Event | Institutional Investor | Definitive Securities Purchase Agreement | Series B ordinary warrants | |||||||
Disclosure of non-adjusting events after reporting period [line items] | |||||||
Number of warrants issued | 1,692,308 | 1,692,308 | |||||
Exercise price of warrants | $ / shares | $ 3.55 | ||||||
Warrant expiration period | eighteen months from issuance |